Noninvasive Brain Stimulation for Mild Cognitive Impairment

Not Applicable

Completed

• Conditions: Cognitive Decline; Cognitive Dysfunction; Memory Impairment; Mild Neurocognitive Disorder; Memory Decline; Mental Deterioration; Memory Loss; Mild Cognitive Impairment
• Interventions: Device: Active rTMS (Bilateral LPC); Device: Active rTMS (Bilateral DLPFC); Device: Placebo rTMS (Inactive)

• Registration Number: NCT03331796
• Lead Sponsor: Palo Alto Veterans Institute for Research

Brief Summary

The goal of this study is to test the efficacy of repetitive Transcranial Magnetic Stimulation (rTMS) as a treatment for Mild Cognitive Impairment (MCI). Participants will be randomly assigned to one of three treatment groups: Group 1: Active Dorsolateral Prefrontal Cortex (DLPFC) rTMS; Group 2: Active Lateral Parietal Cortex (LPC) rTMS; and Group 3: Inactive rTMS (Placebo) control (evenly split between each coil location). Participation in the study takes approximately 7 ½ months-including a 2-to 4-week treatment phase (20 rTMS sessions) and a 6-month follow-up phase.

Detailed Description

This study aims to test the efficacy of a non-pharmacological treatment for MCI that involves noninvasive brain stimulation (NIBS). Early studies in Alzheimer's disease (AD) dementia patients have found that repetitive transcranial magnetic stimulation (rTMS, a form of NIBS) improved global cognitive function and activities of daily living. Given that in AD, neuronal loss and synaptic dysfunction progress along brain networks, the results of these early studies of brain stimulation suggest there is sufficient neuroplasticity in AD for efficacious effects of brain stimulation. Of the very few rTMS studies in MCI that have been published, the effect size appears to be moderately large. However, it is not clear whether the dorsolateral prefrontal cortex (DLPFC), the stimulation site used in the most of the prior MCI/AD rTMS trials, is the optimal site for achieving the most efficacious effects including effects on episodic memory. Importantly, when other investigators used rTMS to stimulate a lateral parietal cortical (LPC) site in healthy young adults, significant effects of rTMS on memory were measureable weeks later. Moreover, functional connectivity of brain regions was selectively increased, including the posterior cingulate cortex (PCC), a "hub" of brain networks that is affected in amnestic MCI.

Because stimulation of the DLPFC and the LPC may each have distinct effects, we designed this pilot trial to have two active rTMS treatment groups: DLPFC and LPC. A third group will receive inactive (placebo) rTMS to achieve a controlled, randomized, double-blind trial. For each of the three groups, stimulation will be bilateral, based on effects achieved in the AD studies. The primary hypothesis is that active rTMS (to either site of stimulation) will be superior to inactive (placebo) rTMS in improving memory. Measures of change in functional connectivity will be computed to examine whether there is evidence that rTMS changes connectivity of the PCC with other regions of the brain. In addition to looking at effects of rTMS on functional connectivity and cognition in relation to the cortical site stimulated, genetic markers will be collected toward addressing heterogeneity of response. To track the durability of rTMS effects on memory, participants will be followed longer than in any prior study (up to 6 months after the intervention). If this study finds rTMS improves memory in older adults with MCI, further clinical development of this non-pharmacological treatment could ultimately improve the lives of millions of older adults who have MCI and are at an increased risk of developing dementia.

Study Timeline

• Study First Submitted: 2017-09-18
• Study First Submitted QC: 2017-11-02
• Study First Posted: 2017-11-06
• Study Start: 2018-05-16
• Primary Completion: 2022-12-19
• Study Completion: 2023-03-28
• Status Verified: 2023-05
• Last Update Submitted: 2023-05-24
• Last Update Posted: 2023-05-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Diagnosed with amnestic Mild Cognitive Impairment (aMCI);
• Stable medications (including any dementia-related meds) for at least 4 weeks prior to Baseline;
• Geriatric Depression Scale score less than 6;
• Ability to obtain a motor threshold, determined during the screening process;
• Study partner available; living situation enables attendance at clinic visits;
• Visual and auditory acuity adequate for neuropsychological testing;
• Good general health with no diseases expected to interfere with the study;
• Participant is not pregnant or of childbearing potential (i.e. women must be 2 years post-menopausal or surgically sterile);
• Modified Hachinski Ischemic score less than or equal to 4;
• Agree to DNA extraction for single nucleotide polymorphism (SNP) genotyping;
• Able to understand study procedures and comply with them for the entire length of the study.

Exclusion Criteria

• Prior exposure to rTMS within the past 12 months;

• Magnetic field safety concern such as a cardiac pacemaker, cochlear implant, implanted device in the brain (deep brain stimulation), or metal fragments or foreign objects in the eyes, skin or body;

• Any significant neurological disease other than suspected incipient Alzheimer's disease;

• Unstable cardiac disease or recent (< 3 months previous) myocardial infarction. Any significant systemic illness or unstable medical condition that could lead to difficulty with protocol adherence;

• History of epilepsy or repetitive seizures, as determined by patient report or chart review;

• History of a medical condition or current use/abuse of medications and substances that increase the risk of a seizure, specifically:

  • Traumatic brain injury within 2 months that would increase the risk for seizure;
  • Unable to safely withdraw, at least 4 weeks prior to Baseline, from medications that substantially increase the risk of having seizures (for example: theophylline, clozapine, and methylphenidate).
  • Current or past history of a mass lesion, cerebral infarct, or other noncognitive active neurological disease that would increase the risk for seizure.
  • Stimulant abuse within the previous 90 days. Cocaine and abuse of amphetamine and methylphenidate are associated with an increased risk of seizures;

• Major depression or bipolar disorder (DSM-IV) within the past 1 year, or psychotic features within the last 3 months that could lead to difficulty with protocol adherence;

• Taking sedative hypnotics or medications with anti-cholinergic properties and unable to withdraw at least 4 weeks prior to Baseline;

• Current alcohol or substance abuse (not including caffeine or nicotine) within the past 1 year, as determined by chart review, participant or study partner report, or greater than "moderate" alcohol use defined by the Quantity-Frequency-Variability Index (Cahalan, Cisin, & Crossley, 1969);

• Any contraindications for magnetic resonance imaging (MRI) studies, e.g. severe claustrophobia, weight above 350 lb maximum allowed by MRI scanner, pregnancy;

• Participation in another concurrent clinical trial;

• Inability or unwillingness of individual or legal representative to give written informed consent.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Active rTMS (Bilateral LPC)	Active rTMS (Bilateral LPC)	One-third of participants will receive active rTMS to the right and left lateral parietal cortex (LPC).
Active rTMS (Bilateral DLPFC)	Active rTMS (Bilateral DLPFC)	One-third of participants will receive active rTMS to the right and left dorsolateral prefrontal cortex (DLPFC).
Placebo rTMS (Inactive)	Placebo rTMS (Inactive)	One-third of participants will receive placebo/inactive rTMS, either to the DLPFC or the LPC. Those receiving placebo rTMS will serve as the control group.

Primary Outcome Measures

Name	Time	Method
Change from Baseline in memory score, as measured by the California Verbal Learning Test-II (CVLT-II)	Baseline, 1 week after completing the 20-session intervention	CVLT-II Trials 1-5 Total raw score (range: 0-80; higher values represent a better outcome)

Secondary Outcome Measures

Name	Time	Method
Change from Baseline in depressive symptoms, as measured by the Geriatric Depression Scale (GDS)	Baseline, 6 months after completing the 20-session intervention	GDS Total score (range: 0-15; higher values represent a worse outcome)
Change from Baseline in everyday functional outcomes, as measured by the Everyday Cognition (ECog) Questionnaire	Baseline, 6 months after completing the 20-session intervention	ECog Scale Total score (range: 39-156; higher values represent a worse outcome)
Change from Baseline in global cognition, as measured by the Montreal Cognitive Assessment (MoCA)	Baseline, 6 months after completing the 20-session intervention	MoCA Total score (range: 0 to 30; higher values represent a better outcome)
Change from Baseline in memory score, as measured by the California Verbal Learning Test (CVLT-II) Trials 1-5 Total raw score	Baseline, 6 months after completing the 20-session intervention	CVLT-II Trials 1-5 Total raw score (range: 0-80; higher values represent a better outcome)
Change from Baseline in visuospatial memory, as measured by the Brief Visuospatial Memory Test-Revised (BVMT-R)	Baseline, 6 months after completing the 20-session intervention	BVMT-R Trials 1-3 Total raw score (range: 0-18; higher values represent a better outcome)
Change from Baseline in speed of processing, as measured by Trail making	Baseline, 6 months after completing the 20-session intervention	Trail making time to complete
Change from Baseline in visuoconstructional function, as measured by the Rey-Osterrieth Complex Figure (ROCF), Copy score	Baseline, 6 months after completing the 20-session intervention	ROCF Copy score (range: 0-36; higher values represent a better outcome)
Change from Baseline in CVLT-II Short-delay free recall	Baseline, 6 months after completing the 20-session intervention	CVLT-II Short-delay free recall correct (range: 0-16; higher values represent a better outcome)
Change from Baseline in levels of brain-derived neurotrophic factor (BDNF)	First Intervention session, to Last Intervention session (The average time frame from the first to the 20th and final session is 18 days)	Plasma levels of BDNF will be measured from fasting blood samples that are collected at the first and last intervention sessions.
Change from Baseline in language function, as measured by Category Fluency (CF)	Baseline, 6 months after completing the 20-session intervention	CF Total number of correct responses in 60 sec (higher values represent a better outcome)
Change from Baseline in CVLT-II Semantic clustering	Baseline, 6 months after completing the 20-session intervention	CVLT-II Semantic clustering (chance-adjusted) Trials 1-5
Change from Baseline in brain functional connectivity	Baseline, 1 week after completing the 20-session intervention	Change from Baseline in Functional connectivity metrics (derived from the pre- and the post-intervention functional magnetic resonance imaging (fMRI) scans rs-fMRI scans) will be computed with respect to: connectivity within the Default Mode Network (DMN), and connectivity between the DMN and the Central Executive Network (CEN).
Change from Baseline in language function, as measured by 42-item Boston Naming Test (BNT)	Baseline, 6 months after completing the 20-session intervention	BNT Total number of correct responses (range: 0-42; higher values represent a better outcome)
Change from Baseline in attention, as measured by the Attentional Network Test (ANT)	Baseline, 6 months after completing the 20-session intervention	ANT correct reaction time

Trial Locations

Locations (1)

VA Palo Alto Health Care System; 🇺🇸 Palo Alto, California, United States